

Help us make a Difference to Meningitis across Asia

‘Finding Friends in Asia’

Speaker:

The Confederation of Meningitis Organisations (CoMO)



Presenters at ASVAC



Prof. Lulu Bravo

Executive Director for the *Philippine Foundation for Vaccination*

Asia Pacific Representative for *CoMO*



Presenters at ASVAC



Chris Head
President of CoMO



Presenters at ASVAC



Bruce Langoulant
Vice President of CoMO
Asia Pacific Leader for CoMO



Session Objectives

1. Describe the goals and relevant activities/strategies of COMO.
2. Explain the WHO's initiative to Defeat Meningitis by 2030.
3. Introduce Project Tracker and add to its effectiveness.
4. Find new Friends in Asia to participate and benefit in 2030.



Introductions

Please introduce yourself with your name, country, and specialism.

What are your expectations of this meeting? Discuss.



About CoMO

Speaker: Prof. Lulu Bravo



About CoMO

CoMO was founded in 2004 and is an international, not-for-profit membership organisation working to reduce the incidence and impact of meningitis worldwide.

Our vision is a world free from meningitis

OUR AIMS

- 1** Member Development and Support: Providing support, tools and networks to assist members in their local efforts to raise awareness of the disease and advocate for prevention in their country/region.
- 2** Global Awareness: Campaigning to raise awareness of meningitis and fighting for improved treatment and global prevention.



CoMO Membership

Europe Africa region


32 Members
20 Countries

Asia Pacific Region

13 Members
9 Countries

Americas Region

25 Members
5 Countries




Key Activities

- World Meningitis Day
- Conferences
- Strengthening Patient Voices Project
- Network communication
- Signposting and referrals



CoMO Change Equation



CoMO Member Advocacy Highlights

#WheresOurVaccine



- Spring 2011 – Counting the Costs
- Jan 2013 – Bexsero gained EMA approval in Europe
- July 2013 – JCVI rejected inclusion
 - MRF & Men Now questioned decision
- Jan 2014 – MRF, scientists & health professionals sent letter to Secretary of State for Health
- 2014 – JCVI recommended intro of vaccine

Beat it Now



CoMO Member Advocacy Highlights: UK

#WheresOurVaccine



Beat it Now



- 2015 – Still no vaccine inclusion 1 year later
- Mar 2015 – MRF & 500 health professionals & scientists sent letter to Secretary of State
 - Both charities add pressure
- 29 Mar 2015 – success!



DHSC Media Centre 
@DHSCmedia

Follow

UK Government strikes deal for world-first national MenB vaccine programme

[#WheresOurVaccine](#) --->

[#HeresOurVaccine!!!](#)



Department
of Health

Government strikes deal for world-first national MenB vacci...

All babies in the UK will soon be vaccinated against meningococcal B (MenB) thanks to a deal agreed this week between the Government and GlaxoSmithKline (GSK), the vacci...
dhmediacentre.tumblr.com

5:00 PM - 28 Mar 2015



CoMO Member Advocacy Highlights: USA

Men B Action Project


- 2 members teamed up in USA in 2017
- Aim: to raise awareness with parents, the medical community and engage policymakers
- Currently campaigning for universities across USA to make the vaccine mandatory



CoMO Member Advocacy Highlights: USA

Men B Action Project

- They've successfully engaged with stakeholders throughout the U.S. – senators, policymakers, school nurses, universities, high schools, nurse practitioners, and health media aimed at students like College Health TV.
- MenB mandate tracker:



**Meningitis B
Action Project**
a joint initiative by The Kimberly Coffey Foundation
and The Emily Stillman Foundation



CoMO Member Advocacy Highlights: Australia

“Eliminating Meningococcal is as easy as ABC.....WY!”

- 2016 - increase in W and Y
- Nov 2016 – campaign began
- Jan 2017- Announced vaccine would be funded for 15-19 year olds in WA
- 2 weeks later - 3 other states followed
- State funding to produce a video on the importance of the vaccine
- Despite awareness campaign, uptake remained poor



CoMO Member Advocacy Highlights: Australia

“Eliminating Meningococcal is as easy as ABC.....WY!”

- Cases were still increasing
- Federal gov’t under pressure from media & communities to do more as cases climbed
- Lobbied State Health minister for protecting under 5s
- Jan 2018 – WA state gov’t announced FREE ACWY program for 1-4 year olds



To Summarise:

- CoMO has 70 members in 35 countries, all committed to a united goal, and we're growing all the time.
- In each region there have been considerable success stories.
- We're grounded in the voice of the patient and supported by robust evidence.
- We coordinate activities and resources for our members to help them achieve their goals.



Meningitis 2030

Speaker: Chris Head



Context: Global Meningitis Burden

- 300,000 deaths from bacterial meningitis in all ages, with the highest burden in babies and young children
(WHO, 2015)
- Mortality rates vary by organism and by WHO region, with the highest overall burden in Africa
- High degree of disabling sequelae among survivors of bacterial meningitis
 - highest proportions for pneumococcal meningitis (25%) and GBS (32%)
 - survivors in low income countries worst affected
 - enormous impact on families and communities, both financially and emotionally



Wilton Park meeting 2017

Global vision for meningitis by 2030 and an action plan



<https://www.wiltonpark.org.uk/wp-content/uploads/WP1521-Report.pdf>



A Roadmap: Structure and Design

The **design of this roadmap** includes three types of phased activities:

1. Setting up a **technical taskforce**
a temporary group of major technical partners historically engaged in meningitis control, to coordinate the development of the roadmap
2. Conducting a **baseline situation analysis (BSA)**
a systematic approach to map/assess where are critical gaps and advances in research and in implementation
3. Conducting an iterative **consultative process**
structured as a collaborative effort of a multi-partner coalition: expert judgement and consensus through technical and public consultations



1. Technical Task Force



Terms of reference

1. To develop the global meningitis roadmap, taking responsibility for the initial steps, as well as for the broad consultation and review cycles
2. To contribute to the finalization and dissemination of technical documents to support their endorsement and the formulation of policy and resolutions by WHO bodies

Current Membership:

- Centers for Disease Control and Prevention (CDC), Atlanta, United States of America: LeAnne Fox, Ryan Novak
- London School of Hygiene and Tropical Medicine (LSHTM), London, United Kingdom: Brian Greenwood, Beate Kampmann, Joy Lawn
- Médecins Sans Frontières and Epicentre, Brussels, Belgium; Geneva, Switzerland; Paris, France: Myriam Henkens, Iza Ciglonecki, Matthew Coldiron
- Meningitis Research Foundation, Bristol, United Kingdom: Linda Glennie, Vincent Smith
- PATH, Seattle, United States of America: Mark Alderson
- UNICEF Program Division, New York City, United States of America: Imran Mirza
- WHO: Regional Office for Africa: Mamoudou Djingarey, Richard Mihigo; Regional Office for the Eastern Mediterranean: Nadia Teleb; Headquarters: Adam Cohen, Tarun Dua, Antoine Durupt, Katya Fernandez, Marie-Pierre Preziosi, Olivier Ronveaux, James Stuart

Expert advisers

- Dominique Caugant, National Institute of Public Health, Oslo, Norway
- Caroline Trotter, University of Cambridge, Cambridge, United Kingdom
- Robert Heyderman, University College London, United Kingdom



2. Baseline situation analysis

- Global and regional burden of meningitis
- Current recommended practice, implementation status, barriers and gap analysis: Prevention and control, Diagnosis and treatment, Disease surveillance, Support and after-care for those affected by meningitis, Advocacy and information
- Contributions from >50 reviewers and authors

**Gap analysis: where we are now and where we want to be
key to informing discussion on direction and priorities for
the roadmap**

https://www.who.int/immunization/research/BSA_20feb2019.pdf?ua=1



3. Iterative Consultation

- **2nd Wilton Park meeting**, Feb 2019: *Defeating Meningitis by 2030 – developing a global roadmap*
 - CoMO attended, alongside reps of our member organisations.
- **Web-based consultation** 3 July to 26 July 2019
 - Stakeholders across the world were contacted to comment on the draft Roadmap.
- Supported by **survey** circulated by the Meningitis Research Foundation (MRF)
 - This survey was much shorter than the public consultation, allowing people with less time or with just one big idea to contribute.
 - Approx 700 responses received.
 - Over 80 countries reached, with responses received in Hindi, Arabic, Spanish, French, Bengali, and more.
 - Accessible vaccination is top of the list for priorities.
- Supported by **survey** circulated by Group B Strep Support
 - This survey related more to Group B Strep specifically and was short like MRF's survey.
 - 2,600+ responses received, 95% within the UK.



The roadmap sets out a global strategy to achieve:

Our vision

Towards a world free of meningitis

The proposed goals to be achieved by 2030 are:

1. Eliminate bacterial meningitis epidemics
2. Reduce cases and deaths from vaccine-preventable bacterial meningitis
(% reduction to be determined)
3. Reduce risk of disability and improve quality of life after all causes of meningitis



Proposed scope

The roadmap focuses on organisms responsible for the majority of acute bacterial meningitis, i.e.


- *Neisseria meningitidis*
- *Streptococcus pneumoniae*
- *Haemophilus influenzae*
- *Streptococcus agalactiae* (Group B streptococcus - GBS)

These pathogens are all preventable or potentially (soon) preventable by vaccination

Meningitis caused by other bacteria or other organisms will be included in strategic goals where applicable




Five pillars for the global roadmap *to achieve the overall goals of the strategy*



The strategic goals, milestones and priority activities will be tailored to the context of each region

Defeating meningitis by 2030: A roadmap (Draft milestones)



Examples of Institutions Involved



The next steps

3rd Wilton Park meeting, 16-18th September 2019

Defeating meningitis by 2030 – developing a global roadmap

This wider meeting in September 2019 including experts in meningitis and disability, representatives from civil society, private sector, and all WHO regions to finalize the roadmap.

SAGE, 8-10th October 2019, Geneva

73rd World Health Assembly, May 2020



To Summarise:

- Men 2030 represents an ambitious but exciting opportunity to defeat meningitis globally
- CoMO and partner member MRF are committed to supporting all elements of the plan
- We need your feedback and help – please join us!



The Meningitis Progress Tracker

Speaker: Bruce Langoulant




Surveillance and the Progress Tracker

- Lack of surveillance for meningitis, especially in comparison to other diseases.
- Disease surveillance was identified by the Global Plan as vital to defeat meningitis.
 - Acts as a tool to track success overtime while holding governments accountable.
- The Tracker was created by the Meningitis Research Foundation and is the first tool of its kind, tracking meningitis and neonatal sepsis in under-5s worldwide.



Meningitis Progress Tracker: An Introduction




Estimates suggest that meningitis and neonatal sepsis combined are the second largest infectious killers of children aged under five. There has been some success in reducing cases and deaths over time, but progress still lags behind other infectious diseases.

<https://public.tableau.com/en-us/gallery/meningitis-progress-tracker>




Meningitis Progress Tracker: Next Steps



Meningitis vaccines have saved thousands of lives yet are still not universally accessible to all children who need them.



Meningitis Progress Tracker: A Closer Look



Meningitis and neonatal sepsis disproportionately affect the world's most vulnerable children. The highest mortality rates from these diseases occur in countries with limited access to skilled health professionals.



Meningitis Progress Tracker: Questions and Your Role

- What can we learn from the Progress Tracker?
- What are the Gaps and Barriers that are influencing the differences?
- How does it aid Meningitis awareness and action?
- How can you feedback to the Tracker so it serves as a useful tool for surveillance and advocacy in your country?



Meningitis Progress Tracker: Contact Details

If you would like to shape the next iteration of the Meningitis Progress Tracker, please email:

Rob Dawson, Director of Advocacy, Communications
and Support for the Meningitis Research Foundation

robd@meningitis.org



Finding Friends in Asia - Workshop



Group Discussion: Regional Issues and Priorities

- 15 mins to discuss the issues and priorities present in different regions
 - 10 mins for feedback
 - 10 mins for discussion
-
- Which countries have more cases of meningitis?
 - Who are some existing contacts you have that would be interested in the Global Plan and the Meningitis Progress Tracker?
 - How can you partner, unite, and team up with CoMO?
 - Become a Friend of CoMO.
 - Sign-up to receive our quarterly external newsletters.
 - Feedback to the Progress Tracker.
 - Email us regarding any questions you may have

Let's connect and stay connected!



Contact Details

To stay in touch please email:
info@comomeningitis.org



Summary

- CoMO's role
- Meningitis 2030 Global Roadmap
- Meningitis Progress Tracker
- Opportunities for you and your stakeholders





Thank you

From: the CoMO Team

